Nevertheless, our goal was to enrol representative patients, since malignant pleural effusions occur in almost 40% of metastatic NSCLC.15 Moreover, the clinical activity of the combination was limited and did not justify further investigation, especially since third-generation EGFR TKIs such as osimertinib have become available and demonstrate significant responses in a similar patient population. Here, EGFR is linked to non-small cell lung carcinoma.